Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo

Gene Therapy

Volumn 5, Issue 6, 1998, Pages 747-754

  Riccioni, T ^a   Cirielli, C ^b   Wang, X ^c   Passaniti, A ^b   Capogrossi, M C ^d  

^a Gene Therapy Unit   (Italy)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c Ist Dermopatico dell' Immacolata   (Italy)

^d Laboratorio di Pntologin Vascolare   (Italy)

Author keywords

Adenovirus; Angiogenesis; Endothelium; Gene therapy; p53

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MATRIGEL; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0031857875     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300681     Document Type: Article

References (41)

1. Liu TJ et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovims. Cancer Res 1994; 54: 3662-3667.
2. dayman GL et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
3. Cirielli C et al. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer 1995; 63: 673-679.
4. Badie B et al. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neural Res 1995; 17: 209-216.
5. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirusmediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55: 4210-4213.
6. Lesoon-VVood LA et al. Systemic gene therapy with p53 reduces growth and métastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6: 395-405.
7. Harris MP et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996; 3: 121-130.
8. Takahashi T et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992; 52: 2340-2343.
9. Fujiwara T et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-1462.
10. Roth JA et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-991.
11. Fujiwara T et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53: 4129-4133.
12. Yonish-Rouach E et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-347.
13. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
14. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res T 1995; 36: 119-126.
15. Van Meir EG et al. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 1994; 8: 171-176.
16. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-6165.
17. Werner H, Karnieli E, Rauscher FJ III, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulinlike growth factor I receptor gene. Proc Natl Acad Sci USA 1996; 93: 8318-8323.
18. Folkman J, Shing Y. Angiogenesis. J Biol Client 1992; 267: 10931-10934.
19. Passaniti A et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519-528.
20. Magovern CJ et al. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Tlier 1997; 8: 215-217.
21. Bates RC, Lincz LF, Burns GF. Involvment of integrins in cell survival. Cancer Metast Rev 1995; 14: 191-203.
22. Schnaper HW et al. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995; 165: 107-118.
23. Grant DS et al. Matrigel induces thymosin t gene in differentiating endothelial cells. J Cell Sci 1995; 108: 3685-3694.
24. Yang C, Chang J, Gorospe M, Passaniti A. Protein tyrosine phosphatase regulation of endothelial cell apoptosis and differentiation. Cell Growth Differ 1996; 7: 161-171.
25. Zhang WVV et al. A. Safety evaluation of AdCMV-p53 in vitro and in vivo. Hum Gene Ther 1995; 6: 155-164.
26. Drazan KE et al. In vivo adenovirus-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery 1994; 116: 197-203.
27. Fan TP, Jaggar R, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogencsis and vascular targeting of gene therapy. Trends Plumnacol Sci 1995; 16: 57-66.
28. Folkman J. Clinical applications of research on angiogenesis. New Engl J Med 1995; 333: 1757-1763.
29. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
30. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-153.
31. O'Reilly MS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
32. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Therapy 1995; 2: 750-756.
33. Wickham TJ, Roelvink PVV, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14: 1570-1573.
34. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin av3 for angiogenesis. Science 1994; 264: 569-571.
35. Albelda S et al. Integrin distribution in malignant melanoma: association of the 3 subunit with tumor progression. Cancer Res 1990; 50: 6757-6764.
36. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the av3 integrins: adhesion mechanism for transformed glial cells. J Clin Invest 1991; 88: 1924-1932.
37. VVickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins av3 and av5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
38. VVickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin av5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994; 127: 257-264.
39. Mühlhauser J et al. VEGF )65 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis m vivo. Circ Res 1995; 77: 1077-1086.
40. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
41. Telford WG, King LE, Fraker PJ. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 1992; 13: 137-143.